Toripalimab after surgery for esophageal cancer that responded fully to treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether the immunotherapy drug Toripalimab can help prevent esophageal cancer from returning after successful surgery and chemotherapy. It is for people whose cancer completely disappeared (pathological complete response) after pre-surgery treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had stage II or III esophageal cancer (squamous cell type).
- You completed chemotherapy or other treatment before surgery, then had surgery to remove all visible cancer.
- After surgery, tests showed no cancer cells left in the tissue or lymph nodes (called pathological complete response).
- You are healthy enough for daily activities (able to care for yourself).
- Your blood counts, liver, and kidney function are within normal limits.
- You have not had other cancer treatments after surgery (like chemo or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Toripalimab given after surgery for esophageal cancer to see if it helps prevent the cancer from coming back. It's for people who already had chemotherapy and immunotherapy before surgery and had all the cancer removed.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This trial tests adding an immunotherapy drug (toripalimab) to chemotherapy and low-dose radiation for people with esophageal cancer that did not shrink after initial treatment. The goal is to see if this combination can help when standard therapy stops working.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial is for people with advanced esophageal cancer that hasn't spread far. After initial treatment with chemotherapy, immunotherapy, and radiation, you'll either get toripalimab or just be watched to see which approach works better.
This trial tests a combination of a new immunotherapy drug (JS004), another immunotherapy (toripalimab), and chemotherapy before and after surgery for people with a certain type of locally advanced esophageal cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.